14 October 2022>: Clinical Research
Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
Zin W. Myint 12ABCDEFG* , Jill M. Kolesar 23CDE , Joseph Robert McCorkle 2CDE , Jianrong Wu 4C , Carleton S. Ellis 23CDE , Danielle E. Otto 23CDE , Peng Wang 12ACDEDOI: 10.12659/MSM.938091
Med Sci Monit 2022; 28:e938091
Table 4 Correlation between 1-month, 3-month, and 7-month abiraterone trough levels and prostate-specific antigen levels stratified by obesity vs non-obesity.
Correlation (PSA, AA) | Spearman rank correlation | P value | Spearman correlation | P value |
---|---|---|---|---|
Obese (BMI >30) | Non-obese (BMI <30) | |||
1 Month | 0.2 | 0.7 | 0.2000 | 0.75 |
3 Months | −0.7 | 0.19 | −0.6000 | 0.40 |
7 Months | −0.00 | 1.0 | – | |
BMI – body mass index, PSA – prostate-specific antigen; AA – abiraterone acetate. |